Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
A user warns against buying the Koreabeautics V2 microneedling pen, claiming it's marketed through fake success stories and is overpriced. Another user shares their experience, acknowledging the pen's quality but agreeing it's too expensive and reliant on frequent needle head replacements.
Kintor Pyrilutamide treatment, a potential hair loss treatment that may become available to the public soon. People have been experimenting with using it in topical form, with mixed results and no reported side effects.
The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.
PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.
New hair loss treatment called scube3 discussed with mixed opinions. Concerns about pharmaceutical companies preferring repetitive treatments over cures due to profit.
A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.
A user accidentally discovered that applying vitamin E oil to their scalp significantly reduced their hair shedding for about 1.5 weeks. They reported improved hair quality and a drastic decrease in hair loss after treatment.
High estradiol levels may contribute to erectile dysfunction (ED) and can be addressed with lifestyle changes or medication. It's important to consult a medical professional for treatment options.
Exosome therapy for hair loss is questioned for its effectiveness and authenticity. Users express skepticism, citing manipulated photos and high costs.
The conversation is about two new videos on exosomes, focusing on how they work and a Q&A session about their use. Specific treatments for hair loss are not discussed.
A user is exploring Kadeso, a product with Capilia Longa™ for hair regrowth, and seeks real-world experiences, comparing it to Minoxidil and Finasteride. They are interested in results, timeframe, side effects, and the credibility of the product's founder.
New hair loss treatments like Shiseido/Replicel and Histogen were discussed, with cautious optimism about their availability by 2018. Setipiprant, Replicel, and Bimatoprost were mentioned as potential treatments expected around 2016-2017.
The conversation discusses concerns about the effectiveness of RU58841 due to high temperatures during delivery. A user reassures that the heat will not affect its efficacy.
The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.
A new treatment, clascoterone 5% solution, shows significant improvement in male hair loss but is considered expensive and only slightly effective by some. It has no side effects and may influence market competition.
New company Amplifica receives $11.8 million for hair loss product development, co-founded by Dr. Maksim Plikus and William Rassman. Users discuss undisclosed product candidates and application methods.
Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.
The conversation is about a user trying to fund lab testing for RU58841 to verify its legitimacy, as there are doubts about its effectiveness. Some users express skepticism about RU58841, suggesting alternatives like KX-826.
Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.
The conversation discusses patient updates on hair loss treatment with Verteporfin after five months, as reported by Dr. Blake Bloxham. Patients voluntarily sent their progress pictures to Dr. Bloxham.
OP is considering using KX-826 for hair loss due to side effects from other treatments like Minoxidil and finasteride. Users discuss the risks and safety of KX-826, with some suggesting caution due to its status as a research chemical.
Kintor is producing a cosmetic with KX826, starting at 0.5% concentration and moving to 1%. The 0.5% concentration wasn't as effective as minoxidil and finasteride, but the 1% concentration shows promise.
Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.
People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.
Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.
The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.
A user's two month update on their hair loss journey and the treatments they are trying, which include exosome injections, minoxidil, finasteride, and RU58841.
The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.